insiderwall
Menu
SuperinvestorInsider
Monopar Therapeutics Inc. MNPR

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel radiopharmaceuticals for oncology and treatments for rare diseases such as Wilson Disease. The company’s pipeline includes advanced radiopharmaceutical candidates designed to target solid tumors for both imaging and therapeu

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees22
TickerMNPR

Statistics

Market Cap$429.6M
Revenue (TTM)$0
Net Income-$13.7M
Net Margin
EPS$-1.93
P/E-31.83
P/S
P/B2.87
EV/EBITDA-15.61
ROE-15.9%
Dividend Yield
Price$64.13

Data: Twelve Data · Revenue = mcap / P/S